The Particle has Landed-Characterizing the Fate of Inhaled Pharmaceuticals, J. Aerosol Med. Pulm. Drug Deliv, vol.23, 2010. ,
Inhaled formulations and pulmonary drug delivery systems for respiratory infections, Adv. Drug Deliv. Rev, vol.85, pp.83-99, 2015. ,
Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds, Front. Pharm, vol.7, 2016. ,
Challenges and strategies in drug delivery systems for treatment of pulmonary infections, Eur. J. Pharm. Biopharm, vol.144, pp.110-124, 2019. ,
Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015. ,
Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome, Eur. J. Pharm. Biopharm, vol.89, pp.163-174, 2015. ,
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 2. Colistin, Antimicrob. Agents Chemother, vol.58, pp.3950-3956, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02477510
Aerosol Therapy with Colistin Methanesulfonate: A Biopharmaceutical Issue Illustrated in Rats, Antimicrob. Agents Chemother, vol.54, pp.3702-3707, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-02472561
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 3. Tobramycin, Antimicrob. Agents Chemother, vol.59, pp.6646-6647, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02477997
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam, Antimicrob. Agents Chemother, vol.60, pp.3196-3198, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02481204
, Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 1. Ciprofloxacin, Moxifloxacin, and Grepafloxacin. Antimicrob. Agents Chemother, vol.58, pp.3942-3949, 2014.
Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: A Phase I, randomized, dose-escalation study, Clin. Ther, vol.35, pp.1571-1581, 2013. ,
Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: A phase I study, Clin. Drug Investig, vol.33, pp.419-427, 2013. ,
Treatment of Bacterial Diseases of the Respiratory Organs, 2011. ,
National Institute of Diabetes and Digestive and Kidney Diseases; 2012-LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, p.20, 2020. ,
Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres, Eur. J. Pharm. Sci, vol.93, pp.184-191, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02470904
ORBIT-2 investigators Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial, Thorax, vol.68, pp.812-817, 2013. ,
Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols, Eur. J. Pharm. Sci, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02477590
Development of liposomal ciprofloxacin to treat lung infections, Pharmaceutics, vol.8, issue.6, 2016. ,
Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination, Pulm. Pharmacol. Ther, vol.50, pp.72-79, 2018. ,
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections, Eur. J. Pharm. Biopharm, vol.117, pp.363-371, 2017. ,
New aerosol formulation to control ciprofloxacin pulmonary concentration, J. Control, vol.271, pp.118-126, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02379277
Ciprofloxacin-Loaded Inorganic-Organic Composite Microparticles To Treat Bacterial Lung Infection, Mol. Pharm, vol.13, pp.100-112, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01373710
Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation, Eur. J. Pharm. Res, vol.1, pp.2-11, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02493122
Aerosol Fluoroquinolone Formulations for Improved Pharmacokinetics, Patent 8815838B2, 2014. ,
Metal complexes of quinolone antibiotics and their applications: An update, Molecules, vol.18, pp.11153-11197, 2013. ,
Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin, Antimicrob. Agents Chemother, vol.36, pp.830-832, 1992. ,
Clinical and chemical interactions between iron preparations and ciprofloxacin, Br. J. Clin. Pharmacol, vol.31, pp.257-261, 1991. ,
Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog, J. Pharm. Sci, vol.85, pp.803-809, 1996. ,
Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier, J. Pharm. Biomed. Anal, vol.53, pp.655-659, 2010. ,
In vitro biopharmaceutical evaluation of ciprofloxacin/metal cation complexes for pulmonary administration, Eur. J. Pharm. Sci, vol.97, pp.92-98, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01416565
Aerosolized Fluoroquinolones and Uses Thereof, 2013. ,
Effect of metal ions on some pharmacologically relevant interactions involving fluoroquinolone antibiotics, Drug Metab. Drug Interact, vol.25, pp.17-24, 2010. ,
Mechanistic Investigation of the Reduction in Antimicrobial Activity of Ciprofloxacin by Metal Cations, Pharm. Res, vol.14, pp.366-370, 1997. ,
Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: Is susceptibility testing justified?, J. Antimicrob. Chemother, vol.65, pp.2373-2375, 2010. ,
Challenges for pulmonary delivery of high powder doses, Int. J. Pharm, vol.548, pp.325-336, 2018. ,
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients, J. Cyst. Fibros, vol.14, pp.507-514, 2015. ,
Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects, Antimicrob. Agents Chemother, vol.55, pp.2636-2640, 2011. ,
Use of aerosolized levofloxacin for treating cystic fibrosis, U.S. Patent 9700564B2, 2017. ,
Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with Pseudomonas aeruginosa, Am. J. Respir. Crit. Care Med, vol.183, pp.1510-1516, 2011. ,
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients, J. Cyst. Fibros, vol.15, pp.495-502, 2016. ,
Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis, Adv. Respir. Dis, vol.8, pp.13-21, 2014. ,
Methods of Treating a Pulmonary Bacterial Infection Using Fluoroquinolones, 2012. ,
Medicines Agency: EMA/CHMP/676680/2014-Assessment Report Quinsair, European Medicines Agency, 2014. ,
Efficacy of Aerosol MP-376, a Levofloxacin Inhalation Solution, in Models of Mouse Lung Infection Due to Pseudomonas aeruginosa, Antimicrob. Agents Chemother, vol.53, pp.3923-3928, 2009. ,
In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis, Antimicrob. Agents Chemother, vol.54, pp.143-148, 2010. ,
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?, Eur. J. Pharm. Biopharm, vol.143, pp.35-43, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02477575
Phase 2b Study Of Inhaled MP-376 (Aeroquin, Levofloxacin Inhalation Solution) In Stable Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (PA) Lung Infection. In A102. Advances in Cystic Fibrosis, p.2339, 2010. ,
Clinical Commissioning Policy: Levofloxacin Nebuliser Solution for Chronic Pseudomonas Lung Infection in Cystic Fibrosis, Adults ,
, , 2018.
Comparison of inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa lung infection in patients with cystic fibrosis: Systematic literature review and network meta-analysis, Clin. Ther, vol.38, pp.2204-2226, 2016. ,
Inhaled antimicrobial therapy-Barriers to effective treatment, Adv. Drug Deliv. Rev, vol.85, pp.24-43, 2015. ,
Inhaled antibiotics: Dry or wet?, Eur. Respir. J, vol.44, pp.1308-1318, 2014. ,
Amorphous Calcium Carbonate Based-Microparticles for Peptide Pulmonary Delivery, ACS Appl. Mater. Interfaces, vol.8, pp.1164-1175, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02484982
Inhalable Microparticles Loaded with A Fluoroquinolone/Metal Cation Complex for the Treatment of Respiratory Diseases, Patent WO2018104759A1, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02485017
Development and Biopharmaceutical Evaluation of Fluoroquinolone-loaded Microparticles for Inhalation, 2018. ,
Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs, Int. J. Pharm, vol.549, pp.306-316, 2018. ,
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients, vol.44, pp.547-558, 2009. ,
Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin, J. Antimicrob. Chemother, vol.73, pp.2762-2769, 2018. ,
PEGylation of tobramycin improves mucus penetration and antimicrobial activity against Pseudomonas aeruginosa biofilms in vitro, Mol. Pharm, vol.15, pp.1643-1652, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02379306
Diffusion retardation by binding of tobramycin in an alginate biofilm model, PLoS ONE, vol.11, 2016. ,
Efficacy of Ciprofloxacin and Its Copper Complex against Pseudomonas aeruginosa Biofilms, Aaps Pharmscitech, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02477817
Drug Delivery Strategies to Treat Pseudomonas aeruginosa Biofilm Infections, 2018. ,
Animal models of chronic lung infection with Pseudomonas aeruginosa: Useful tools for cystic fibrosis studies, Lab. Anim, vol.42, pp.389-412, 2008. ,
Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model, J. Infect. Dis, vol.192, pp.410-419, 2005. ,
Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin, J. Cyst. Fibros, vol.10, pp.166-174, 2011. ,
Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies, PLoS ONE, vol.11, 2016. ,
Copper-heparin inhalation therapy to repair emphysema: A scientific rationale, Int. J. Chronic Obstr. Pulm. Dis, vol.14, pp.2587-2602, 2019. ,
Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma, Chest, vol.129, pp.1288-1297, 2006. ,
A Perspective-can copper complexes be developed as a novel class of therapeutics? Dalton Trans, vol.46, pp.10758-10773, 2017. ,
The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing lysyl oxidase expressions, Biol. Trace Elem. Res, vol.162, pp.189-199, 2014. ,
, Clinical Pharmacokinetics of Inhaled Antimicrobials, vol.54, pp.473-492, 2015.
Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products, Eur. J. Pharm. Sci, vol.113, pp.18-28, 2018. ,
Inhaled Antibiotics for Lower Airway Infections, Ann. Am. Thorac. Soc, vol.11, pp.425-434, 2014. ,
Pulmonary Delivery of a Fluoroquinolone, 2009. ,
A. 5.16-Ionization Constants and Ionization Profiles, In Comprehensive Medicinal Chemistry II ,
URL : https://hal.archives-ouvertes.fr/hal-02432849
, , pp.357-397, 2007.
The Effect of Temperature and pH on the Solubility of Quinolone Compounds: Estimation of Heat of Fusion, Pharm. Res, vol.11, pp.522-527, 1994. ,
Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials, Eur. J. Pharm. Sci, vol.93, pp.29-37, 2016. ,
Influence of pH and antibiotic solubility on the removal of ciprofloxacin from aqueous media using montmorillonite, Appl. Clay Sci, vol.114, pp.69-76, 2015. ,
Pharmaceutical Formulation with an Insoluble Active Agent for Pulmonary Administration, Patent EP1589947B1, 2016. ,
The PulmoSphere TM platform for pulmonary drug delivery, Ther. Deliv, vol.5, pp.277-295, 2014. ,
Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere TM Technology, J. Aerosol Med. Pulm. Drug Deliv, vol.24, pp.175-182, 2011. ,
Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy, Int. J. Pharm, vol.548, pp.182-191, 2018. ,
Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD, Eur. Respir. J, vol.40, p.2817, 2012. ,
Ciprofloxacin DPI (BAY q3939)-Briefing Document for FDA Advisory Committee Meeting, vol.FDA, p.146, 2017. ,
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase II randomised study, Eur. Respir. J, vol.41, pp.1107-1115, 2013. ,
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis, Contemp. Clin. Trials, vol.58, pp.78-85, 2017. ,
RESPIRE 2: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis, Eur. Respir. J, vol.51, 2018. ,
RESPIRE: Breathing new life into bronchiectasis, Eur. Respir. J, 2018. ,
Ciprofloxacin Dry Powder for Inhalation (DPI)-Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC), vol.FDA, p.51, 2017. ,
Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions, Eur. J. Pharm. Biopharm, vol.131, pp.120-129, 2018. ,
Recent Trends in Preparation of Poly(lactide-co-glycolide) Nanoparticles by Mixing Polymeric Organic Solution with Antisolvent, J. Nanomater, vol.794601, 2015. ,
Efficacy of Poly-Lactic-Co-Glycolic Acid Microand Nanoparticles of Ciprofloxacin Against Bacterial Biofilms, J. Pharm. Sci, vol.105, pp.3115-3122, 2016. ,
Accelerated in-vitro release testing methods for extended-release parenteral dosage forms, J. Pharm. Pharmacol, vol.64, pp.986-996, 2012. ,
Ciprofloxacin-encapsulated poly(dl-lactide-co-glycolide) nanoparticles and its antibacterial activity, Int. J. Pharm, vol.352, pp.317-323, 2008. ,
Antibacterial efficacy of inhalable antibiotic-encapsulated biodegradable polymeric nanoparticles against E. coli biofilm cells, J. Biomed. Nanotechnol, vol.6, pp.391-403, 2010. ,
Antibacterial Efficacy of Inhalable Levofloxacin-Loaded Polymeric Nanoparticles Against E. coli Biofilm Cells: The Effect of Antibiotic Release Profile, Pharm. Res, vol.27, pp.1597-1609, 2010. ,
Preparation, in vitro release and antibacterial activity evaluation of rifampicin and moxifloxacin-loaded poly(D,L-lactide-co-glycolide) microspheres, Artif. Cells Nanomed. Biotechnol, vol.47, pp.790-798, 2019. ,
In vitro behavior of poly-lactic-co-glycolic acid microspheres containing minocycline, metronidazole, and ciprofloxacin, J. Investig. Clin. Dent, vol.8, 2017. ,
Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease, Drugs, vol.79, pp.555-562, 2019. ,
Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages, Front. Microbiol, vol.9, p.915, 2018. ,
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): Two phase 3, randomised controlled trials, Lancet Respir. Med, vol.7, pp.213-226, 2019. ,
Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans, Adv. Drug Deliv. Rev, vol.75, pp.53-80, 2014. ,
Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients, Pulm. Ther, vol.5, pp.127-150, 2019. ,
Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis, Drug Des. Dev, vol.12, pp.4059-4066, 2018. ,
The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy, Front. Cell Infect. Microbiol, 2014. ,
Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever, Antimicrob. Agents Chemother, vol.58, pp.5510-5518, 2014. ,
Formulation of rifampicin-cyclodextrin complexes for lung nebulization, J. Control. Release, vol.129, pp.93-99, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-01102812
Using polar ion-pairs to control drug delivery to the airways of the lungs, Mol. Pharm, 2020. ,
Incorporation of farnesol significantly increases the efficacy of liposomal ciprofloxacin against Pseudomonas aeruginosa biofilms in vitro, Mol. Pharm, vol.13, pp.2760-2770, 2016. ,
Structure and stability of fluoroquinolone-(2-hydroxypropyl) -?-cyclodextrin complexes as perspective antituberculosis drugs, Mosc. Univ. Chem. Bull, vol.71, pp.1-6, 2016. ,
Absorption of Polyethylene Glycol (PEG) Polymers: The Effect of PEG Size on Permeability, J. Pharm. Sci, vol.98, pp.2847-2856, 2009. ,
Microbial esterases and ester prodrugs: An unlikely marriage for combating antibiotic resistance, Drug Dev. Res, vol.80, pp.33-47, 2019. ,
Pro-Moieties of Antimicrobial Peptide Prodrugs, Molecules, vol.20, pp.1210-1227, 2015. ,
Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles, J. Nanobiotechnol, vol.17, p.103, 2019. ,
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI